Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study

Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study

Background and aimsIn recent years, biological agents, such as anti-TNF-α blockers, have been introduced and have shown efficacy in pediatric patients with inflammatory bowel disease (IBD). Here, the prescription mode differentiated into a first/second line application, and efficacy and side effects...

Full description

Bibliographic Details
Main Authors: Merle Claßen, Jan de Laffolie, Martin Claßen, Alexander Schnell, Keywan Sohrabi, André Hoerning
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pediatrics
Subjects:
Crohn’s disease
ulcerative colitis
anti-TNF-α inhibitor therapy
first-line therapy
pediatric inflammatory bowel disease (IBD)
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.903677/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.903677/full

Similar Items